Key facts
- Whitefort Capital Management, LP filed SCHEDULE 13D/A for Arbutus Biopharma Corp Common Shares, without par value (ABUS).
- Disclosed ownership: 7%.
- Date of event: 20 Feb 2025.
Key filing fact
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP | 7% | 13,307,967 | 0 | 13,307,967 | /s/ David Salanic | David Salanic, Co-Managing Member of Whitefort Capital GP, LLC, its General Partner | 0001704387 |
| Whitefort Capital GP, LLC | 7% | 13,307,967 | 0 | 13,307,967 | /s/ David Salanic | David Salanic, Co-Managing Member | |
| Whitefort Capital Management, LP | 7% | 13,307,967 | 0 | 13,307,967 | /s/ David Salanic | David Salanic, Co-Managing Partner | 0001884931 |
| Whitefort Capital Management GP, LLC | 7% | 13,307,967 | 0 | 13,307,967 | /s/ David Salanic | David Salanic, Co-Managing Member | |
| David Salanic | 7% | 13,307,967 | 0 | 13,307,967 | /s/ David Salanic | David Salanic | |
| Joseph Kaplan | 7% | 13,307,967 | 0 | 13,307,967 | /s/ Joseph Kaplan | Joseph Kaplan |
CIK / CUSIP context first